Over 60% of small pharma units face shutdown risk
pre-market1 source ↓written by the desknot a recommendation
- of India’s
- 60%
- small and medium
- 8,500
- due to non-compliance
- 31 Dec 2023
- SME segment
- ₹75,000 cr
- domestic pharmaceutical market
- ₹2.5 lakh cr
More than 60% of India’s 8,500 small and medium pharmaceutical manufacturers may shut down by 31 Dec 2023 due to non-compliance with revised GMP norms. This could disrupt supplies of essential medicines and impact the ₹75,000 cr SME segment of the ₹2.5 lakh cr domestic pharmaceutical market. The situation raises concerns over employment and export markets.
Not investment advice. For informational purposes only.